Announcement • May 26
Novacyt S.A., Annual General Meeting, Jun 30, 2026 Novacyt S.A., Annual General Meeting, Jun 30, 2026. Location: hotel hilton paris charles de gaulle aeroport, paris France Announcement • May 21
Novacyt S.A. Launches Yourgene Insight DPYD Assay Novacyt S.A. announced the launch of Yourgene Insight DPYD assay, an assay utilizing genetic Insights for safer chemotherapy treatments to align with updated testing guidelines. Yourgene Insight DPYD is a simple-to-use genotyping test that can identify cancer patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency, which can cause severe and sometimes lethal side effects in patients being treated with chemotherapeutic drug 5-Fluorouracil (5-FU), commonly used in the treatment of colorectal, head and neck, breast, pancreatic and stomach cancers. Over two million cancer patients globally are treated with fluoropyrimidines (including 5-FU) each year; 10-20% of these patients suffer severe, and sometimes fatal side effects associated with DPD deficiency. Screening patients for DPYD variants allows treatments to be adjusted accordingly. Following updated guidelines from a joint consensus of organizations such as AMP (Association for Molecular Pathology) and ACMG (American College of Medical Genetics and Genomics), the 2019 original Yourgene DPYD test has been enhanced to enable the number of variants to be detected to increase from six to 19, including the 14 recommended by these updated guidelines. The product has been launched for Research Use Only (RUO) initially with In Vitro Diagnostic Regulation (IVDR) and other regulatory territory approvals to follow in due course. Many countries have already implemented DPYD genotyping ahead of prescribing chemotherapy treatment and there is a mixed model of private pay and reimbursement. The Yourgene Insight DPYD test has the same workflow and format as the original DPYD kit, with ready-to-use reagents, simple data interpretation to identify the presence or absence of 19 variants and a fast turnaround time enabling results to be provided the same day, ensuring there is no delay in patients starting their chemotherapy treatment. The Company has continued to invest in research and development to expand its product portfolio, and it is encouraging to see this investment translating into commercially launched products and tangible pipeline progress. Announcement • May 10
Novacyt S.A. Announces Departure of Chief Scientific Officer and Board Member Dr Joanne Mason, Effective 7 May 2026 Novacyt S.A. announces that Dr Joanne Mason is stepping down as Chief Scientific Officer and a member of the Board of Novacyt, with immediate effect, to enable her to pursue other business opportunities. Announcement • May 02
Novacyt S.A. Provides Earnings Guidance for Fiscal Year 2026 Novacyt S.A. provided earnings guidance for Fiscal Year 2026. For the year, the company's outlook for FY26 looks strong, as company targets double digit revenue growth year-on-year. Announcement • Apr 08
Novacyt S.A. to Report Fiscal Year 2025 Results on Apr 30, 2026 Novacyt S.A. announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 30, 2026 Announcement • Mar 03
Novacyt S.A. has filed a Follow-on Equity Offering in the amount of €0.784736 million. Novacyt S.A. has filed a Follow-on Equity Offering in the amount of €0.784736 million.
Security Name: Shares
Security Type: Common Stock
Securities Offered: 1,961,840
Price\Range: €0.4
Transaction Features: Rights Offering Announcement • Jan 21
Novacyt S.A. Provides Earnings Guidance for the Second Half and Year Ended December 31, 2025 Novacyt S.A. provided earnings guidance for the second half and year ended December 31, 2025. For the period, the company expects Group maintained sequential half-year growth over three consecutive periods, with revenue rising from £9.6 million in H2 2024 to £10.2 million in H2 2025
For the year, the company expects Group statutory revenue for Fiscal Year 2025 is expected to be c. £20.0 million (FY 2024: £19.6 million), in line with market expectations of £19.8 million. Announcement • Oct 22
Novacyt S.A. Provides Earnings Guidance for the Second Half of fiscal year 2025 and for the full fiscal year 2026 Novacyt S.A. provided earnings guidance for the Second Half of fiscal year 2025 and for the full fiscal year 2026. For the second half of fiscal year 2025, company expected to see a slight increase revenues vs first half of 2025, driven primarily by increased instrument sales, with new orders received from the recently launched LightBencx Discover instrument.
For the fiscal year 2026, company expected to deliver double digit revenue growth year-on-year (from FY26). Announcement • Sep 18
Novacyt S.A. to Report First Half, 2025 Results on Sep 30, 2025 Novacyt S.A. announced that they will report first half, 2025 results on Sep 30, 2025 Announcement • Jul 16
Novacyt S.A. Announces the Launch of LightBench® Discover Novacyt S.A. announced the launch of LightBench® Discover, a high-precision 3-in-1 instrument for genomic research labs conducting long-read sequencing. The concept for the LightBench® Discover was developed following a close collaboration with PacBio®, where Yourgene Health became a PacBio® Compatible Partner for the original LightBench®? in November 2023. As part of product development for LightBench® Discover, Novacyt deployed prototype instruments into the field to gather customer feedback on user experience, develop protocols and run real world samples to assess the instruments' performance. LightBench® Discover is an integrated single benchtop solution that replaces the need for multiple instruments in labs conducting long-read HiFi sequencing, who need both large fragment analytics (larger than 20 kilobases) and DNA size selection. In addition, LightBench®? Discover also delivers fluorometric quantification. Researchers benefit from a cost-effective, high-performance system that enhances efficiency, whilst eliminating the need to invest in multiple instruments with separate service contracts and software platforms. The product has extended capabilities (compared to the original LightBench®) for large fragment analytics up to 150 kilobases, along with size selection and quantification functions, making it ideal for research applications utilising long read sequencing on the PacBio Revio®? or Vegatm systems. The Company has released the Technical Note showcasing data from its collaborator The CoLab at the HudsonAlpha Institute for Biotechnology in Alabama, US. The Technical Note will be hosted on the Company's website <URL> and on the PacBio®? Compatible Partners webpage. Announcement • May 15
Novacyt S.A., Annual General Meeting, Jun 19, 2025 Novacyt S.A., Annual General Meeting, Jun 19, 2025. Location: hotel hilton paris charles de gaulle aeroport, velizy villacoublay France Announcement • Apr 22
Novacyt S.A. to Report Fiscal Year 2024 Results on Apr 30, 2025 Novacyt S.A. announced that they will report fiscal year 2024 results at 9:00 AM, Central European Standard Time on Apr 30, 2025 Announcement • Feb 22
Novacyt S.A. Announces IVDR Accreditation for Yourgene®? QST*R Base Assay Novacyt S.A. announced that it has receivedaccreditation under the new EU requirements of theIn VitroDiagnostic Regulation ("IVDR") for theYourgene® QSTRBaseassay.TheYourgene® QSTRBaseis a Class Cin vitromedical device under IVDR and is intended for use by healthcare professionals within a molecular laboratory environment. Yourgene® QSTR Base is a highly multiplexed, single tube assay containing 22 markers for rapid diagnosis of the common autosomal and sex chromosome aneuploidies during pregnancy. For those women identified as being at high risk of carrying a fetus with one of these conditions, chorionic villus sampling (10-12 weeks) or amniocentesis (14-18 weeks) is offered and QSTR Base would then be used by the laboratory. Autosomal markers are used to detect the three most common viable autosomal trisomies: trisomy 21 (Down's syndrome), trisomy 18 (Edwards' syndrome) and trisomy 13 (Patau's syndrome). The chosen markers are highly informative with results obtained in >99% of samples. IVDR ensures that the Yourgene® QSTR Base assay, which is manufactured for sale in the EU, is assessed against stringent quality, safety and performance requirements. Manufacturers must provide considerable evidence of scientific validity, as well as data demonstrating analytical and clinical performance of the tests. The Yourgene® QSTR Base assay was assessed by British Standards Institution (BSI), an independent conformity assessment body, and was shown to conform to the new regulations. Announcement • Oct 08
Novacyt S.A. Closure of IT-IS International Limited Novacyt S.A. announced the closure of its IT-IS International Limited ("IT-IS") subsidiary, effective immediately. IT-IS, a Stokesley-based manufacturer of rapid-PCR instruments, was acquired by Novacyt in 2020 to support the Group's response to COVID-19, where it facilitated the full delivery of the Group's contracts during the period. The PCR instrumentation market has since become saturated, with IT-IS subsequently experiencing several consecutive loss-making years. IT-IS contributed £0.3m to the Group's total revenue in H1 2024 (H1 2023: £0.6million). The Intellectual Property ("IP") that exists within IT-IS will be retained to allow Novacyt to continue an ongoing IP infringement dispute with Roche Diagnostics GmbH. The dispute, instigated by IT-IS, dates back over five years and is currently progressing through the German courts. The Group will provide further updates on the dispute when appropriate. Announcement • Sep 26
Novacyt S.A. Appoints John Brown Cbe as Chairman, Effective from 1 October 2024 Novacyt S.A. announces the appointment of Dr. John Brown CBE as Chairman effective from 1 October 2024. Dr. Brown was appointed Non-executive Director of Novacyt in September 2023 following the acquisition of Yourgene Health and will succeedJames Wakefield, who is retiring from the Board having been Chairman since before the company joined AIM in 2017. Dr. Brown has over 38 years industry experience, which includes significant capital markets and board experience in the healthcare and life sciences sector. He is currently Chairman of Laverock Therapeutics Ltd. and Calcivis Ltd, and until recently was Chairman of Synpromics Ltd, BioCity Group and the Cell and Gene Therapy Catapult. Previously, he was Chairman of Kyowa Kirin International plc, BTG plc, Axis-Shield plc, Touch Bionics Ltd. and CXR Biosciences Ltd. and Senior Non-Executive Director of Quantum Pharma plc. Dr. Brown was appointed to the Board of Yourgene Health in July 2019 as a Non-executive Director and became Chairman in April 2022. Announcement • Sep 12
Novacyt S.A. to Report First Half, 2024 Results on Sep 26, 2024 Novacyt S.A. announced that they will report first half, 2024 results on Sep 26, 2024 Announcement • May 22
Novacyt S.A., Annual General Meeting, Jun 26, 2024 Novacyt S.A., Annual General Meeting, Jun 26, 2024. Location: velizy villacoublay France Announcement • May 21
Novacyt S.A. to Report Fiscal Year 2023 Results on May 30, 2024 Novacyt S.A. announced that they will report fiscal year 2023 results on May 30, 2024 Announcement • May 01
Novacyt S.A. Notes DHSC Application for Summary Judgment Dismissed Novacyt S.A. noted the judgment by Mrs. Justice Jefford following the Pre-Trial Review heard on 30 April 2024. Mrs. Justice Jefford has dismissed the application by the Department of Health and Social Care ("DHSC") for summary judgment. The Pre-Trial Review has now concluded, and the trial hearing has been listed to commence on 10 June 2024, and finish on 4 July 2024. The Company expects the court to reserve judgment, meaning that the outcome of the trial will not be known on 4 July 2024. Announcement • Sep 13
Novacyt S.A. to Report Q2, 2023 Results on Sep 28, 2023 Novacyt S.A. announced that they will report Q2, 2023 results on Sep 28, 2023 Announcement • Jul 28
Novacyt S.A. Provides Group Revenue Guidance for the First Half Ended June 30, 2023 Novacyt S.A. provided group revenue guidance for the first half ended June 30, 2023. Group revenue for first half 2023 expected to be £3.3 million of which £0.5 million relates to COVID-19 (first half 2022: £16.5 million of which £13.0 million relates to COVID-19). Announcement • May 10
Novacyt S.A., Annual General Meeting, Jun 15, 2023 Novacyt S.A., Annual General Meeting, Jun 15, 2023, at 14:00 Central European Standard Time.